Alnylam prelim 2023 product rev $1.24B (+39% YoY); Q4 growth across all drugs

ALNYLAM PHARMACEUTICALS, INC.

2023-FY EPS reported -$3.52 revenue$1,828,292,000

Full-year 2023 global net product revenues $1,241M, up 39% YoY (39% constant currency).
Q4 2023 revenues: ONPATTRO $79M, AMVUTTRA $175M, GIVLAARI $59M, OXLUMO $33M.
Year-end cash & investments ~$2.4B, up from $2.2B at end of 2022.
Over 4,060 patients on ONPATTRO/AMVUTTRA; over 650 on GIVLAARI, over 430 on OXLUMO at year-end 2023.
Management cites strong patient demand and commercial execution; HELIOS-B readout expected early 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

ALNYLAM PHARMACEUTICALS, INC. reported fourth quarter 2023 results: revenue $346 million.

Period: fourth quarter 2023
Revenue: $346 million
Result: preliminary results

Exact text from the filing

On January 7, 2024, Alnylam Pharmaceuticals, Inc. (the “Company”) announced its preliminary fourth quarter and full year 2023 global net product revenues of approximately $346 million and $1,241 million, respectively, for ONPATTRO® (patisiran), AMVUTTRA® (vutrisiran), GIVLAARI® (givosiran) and OXLUMO® (lumasiran).

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

ALNYLAM PHARMACEUTICALS, INC. reported full year 2023 results: revenue $1,241 million.

Period: full year 2023
Revenue: $1,241 million
Result: preliminary results

Exact text from the filing

On January 7, 2024, Alnylam Pharmaceuticals, Inc. (the “Company”) announced its preliminary fourth quarter and full year 2023 global net product revenues of approximately $346 million and $1,241 million, respectively, for ONPATTRO® (patisiran), AMVUTTRA® (vutrisiran), GIVLAARI® (givosiran) and OXLUMO® (lumasiran).

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

ALNYLAM PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-24-003854

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.